Yn y dyfodol, bydd meddyginiaethau eraill sydd yn y categori amddifad ac amddifad iawn, ac mae angen i mi sicrhau y gall ein proses arfarnu yng Nghymru eu gwerthuso’n effeithiol.  Rwyf felly wedi gofyn i’r Prif Swyddog Fferyllol drefnu adolygiad [gyda phawb perthnasol sydd â buddiant] o’n proses arfarnu i ymdrin â’r meddyginiaethau newydd ac arloesol hyn ar gyfer clefydau prin. Byddaf yn adrodd i’r Cynulliad Cenedlaethol ar hynt y gwaith maes o law.
In the future there will be other medicines which fall into the category of orphan and ultra orphan status and I need to ensure our appraisal process in Wales can effectively evaluate them.  I have therefore  asked the Chief Pharmaceutical Officer to set up a review  [involving all relevant interests] of our appraisal process to deal with these new, innovative medicines for rare diseases. I will report back to the National Assembly on progress as it becomes available.